ISRCTN33932204 https://doi.org/10.1186/ISRCTN33932204

# A prospective study using the KerraCel™ dressing on multiple wound types

**Submission date**
15/09/2021

**Recruitment status**
No longer recruiting

**Registration date**
15/11/2021

**Overall study status**
Completed

**Last Edited**
20/11/2025

**Condition category**
Injury, Occupational Diseases, Poisoning

[ ] Prospectively registered
[ ] Protocol
[ ] Statistical analysis plan
[X] Results
[ ] Individual participant data

## Plain English summary of protocol

Background and study aims
The KerraCel™ dressing is a CE-marked product that has been on the market since 2013. It contains gelling fibers that can soak up the fluid that can be created by wounds on the skin. The aim of the study is to collect additional information on the dressing to show that it is working as intended.

Who can participate?
Patients aged 22 years or older and being seen for these types of wounds: Oncology wounds, traumatic wounds, cavity wounds, skin donor site. Examples of these can be: Oncology - radiation burns, cancerous wounds or wounds that occur after surgical removal of cancer. Traumatic - abrasions (deep scrapes) or lacerations. Cavity - wounds in a cavity (such as addomen or chest). Donor sites where skin has been removed for grafting.

What does the study involve?
For patients who meet the requirements to participate, you will be seen 4 times in the office /clinic. On the first visit, you will have a picture taken of the wound and the dressing put over the wound. You will come in 2 additional times, approximately 7 days apart from each visit, to have another picture of the wound taken and another dressing placed over the wound. A final visit will occur (again approximately 7 days from the 3rd visit), where the dressing will be removed and another picture is taken. No surveys will be completed for this study and only small amounts of information such as medical history, medication use, and information about your wound will be collected.

What are the possible benefits and risks of participating?
Possible benefits of the study are the wound dressing may help manage your wound healing, additional follow-up by the staff at the hospital since this is a study, use of a dressing not currently in use at the facility.

Possible risks of participating are the same risks that would occur for treating any open wound with a wound dressing: skin irritation, redness, possible infection, delay in wound healing. One possible risks for this type of dressing is some of the gel material could remain in the wound.

Where is the study run from?
Wythenshawe Hospital (UK)

When is the study starting and how long is it expected to run for?
April 2021 to June 2023

Who is funding the study?
KCI® USA, Inc (now a part of 3M) (USA)

Who is the main contact?
Mrs Lawrie Rogerson-Wynne, Lawrie.rogerson@mft.nhs.uk

# Contact information

### Type(s)
Public

### Contact name
Mrs Lawrie Rogerson-Wynne

### Contact details
Research Office, First floor, NIHR Research Building
Wythenshawe Hospital
Southmoor Road
Manchester
United Kingdom
M23 9QZ
+44 (0)161 291 4850
Lawrie.rogerson@mft.nhs.uk

### Type(s)
Scientific

### Contact name
Mr Eric Synatschk

### Contact details
KCI USA, Inc.
6203 Farinon Drive
San Antonio
United States of America
78249
+1 5126625943
esynatschk@mmm.com

# Additional identifiers

### Clinical Trials Information System (CTIS)
Nil known

### Integrated Research Application System (IRAS)
288315

### ClinicalTrials.gov (NCT)
Nil known

### Protocol serial number
KERA_CEL-PMCF007, IRAS 288315, CPMS 47700

# Study information

### Scientific Title
A prospective, observational, Post Market Clinical Follow-up (PMCF) study in patients using 3M™ KerraCel™ Gelling Fiber dressing

### Study objectives
Current hypothesis as of 18/03/2022:
The aim of this study is to describe the population and indications of the KerraCel™ Dressing to demonstrate that the product is performing as expected and is safe specifically on the identified wound types, where it has been identified that additional evidence is needed to support the Clinical Evaluation Report (CER).

———

Previous hypothesis:
The aim of this study is to describe the population and indications of the KerraCel™ Dressing to demonstrate that the product is performing as expected and is safe specifically on oncological and traumatic wounds, where it has been identified that additional evidence is needed to support the Clinical Evaluation Report (CER).

### Ethics approval required
Old ethics approval format

### Ethics approval(s)
Approved 23/04/2021, London-Westminster Research Ethics Committee (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, UK; +44 (0)207 104 8388; westminster.rec@hra.nhs.uk), ref: 21/PR/0337

### Study design
Single center observational study

### Primary study design
Observational

### Study type(s)
Treatment

### Health condition(s) or problem(s) studied

Oncological wounds (e.g. radiation burns, cancerous wounds and surgical wounds once the cancerous tissue has been removed), traumatic wounds (e.g. abrasions and lacerations), cavity wounds (such as abdominal or thoracic) and wounds created from skin donor sites

### Interventions
Patients will be seen and evaluated by a clinician to determine if their wound is appropriate to be treated with the KerraCel™ dressing. If yes, the clinician will make general observations of the wound and then dress the wound. Pictures will be taken of the wound initially and at each dressing change.

Patients will be seen 4 times in the office/clinic. On the first visit, a picture is taken of the wound and the dressing put over the wound. At 2 additional visits, approximately 7 days apart from each visit, another picture of the wound is taken and another dressing is placed over the wound. A final visit will occur (again approximately 7 days from the 3rd visit), where the dressing will be removed and another picture taken.

### Intervention Type
Device

### Phase
Phase IV

### Drug/device/biological/vaccine name(s)
3M™ KerraCel™ Gelling Fiber Dressing

### Primary outcome(s)
Treatment-related adverse events measured using patient records up to the final visit (~21-28 days)

### Key secondary outcome(s))
Wound healing and wound bed preparation by visual inspection of at baseline, ~day 7, 14, 21-28:
1. Decrease in wound size (volume, area, or depth)
2. Increase in % of wound granulation tissue
3. Wound moisture evaluation defined as wound exudate levels indicated as optimal
4. Decrease in % of nonviable tissue

### Completion date
21/06/2023

## Eligibility

### Key inclusion criteria
Current inclusion criteria as of 18/03/2022:
1. Subjects who have been diagnosed with an oncological wound (e.g. radiation burns, cancerous wounds, and surgical wounds once the cancerous tissue has been removed), or traumatic wound (e.g. abrasions and lacerations), or cavity wound (wounds in a cavity) or skin donor site
2. Must be able to provide informed consent

3. Only one wound may be treated per subject for the study
4. Aged ≥22 years

———

Previous inclusion criteria:
1. Subjects who have been diagnosed with an oncological wound (e.g. radiation burns, cancerous wounds, and surgical wounds once the cancerous issue has been removed) or traumatic (e.g. abrasions and lacerations) wound.
2. Must be able to provide informed consent.
3. Only one wound may be treated per subject for the study.
4. Age ≥22 years.

## Participant type(s)
Patient

## Healthy volunteers allowed
No

## Age group
Mixed

## Lower age limit
22 years

## Upper age limit
100 years

## Sex
All

## Total final enrolment
48

## Key exclusion criteria
Current exclusion criteria as of 18/03/2022:
1. Has a known allergy to the dressing material
2. Has a wound that has uncontrolled heavy bleeding
3. Wound or burn larger than 20 cm in any direction
4. Pregnant or breastfeeding

———

Previous exclusion criteria:
1. Has a wound that requires packing of a body cavity with the KerraCel™ dressing, per the manufacturer’s instructions for use.
2. Has a wound that has not achieved hemostasis, per the manufacturer’s instructions for use.
3. Wound or burn larger than 20cm in any direction.
4. Pregnant or breastfeeding.

## Date of first enrolment
01/09/2021

**Date of final enrolment**
09/06/2023

# Locations

**Countries of recruitment**
United Kingdom

England

**Study participating centre**
**Wythenshawe Hospital**
University of Manchester & Manchester University NHS Foundation Trust
Southmoor Road
Manchester
England
M23 9QZ

# Sponsor information

**Organisation**
KCI (United States)

**ROR**
https://ror.org/00wc6ay63

# Funder(s)

**Funder type**
Industry

**Funder Name**
Kinetic Concepts

**Alternative Name(s)**
Kinetic Concepts, Inc., KCI USA, KCI

**Funding Body Type**
Private sector organisation

**Funding Body Subtype**

For-profit companies (industry)

### Location
United States of America

# Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary
Not expected to be made available

### Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Basic results | | | 20/11/2025 | No | No |
| HRA research summary | | | 28/06/2023 | No | No |